|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, et al: Changing epidemiology of
small-cell lung cancer in the United States over the last 30 years:
analysis of the surveillance, epidemiologic, and end results
database. J Clin Oncol. 24:4539–4544. 2006.PubMed/NCBI
|
|
3
|
Wahbah M, Boroumand N, Castro C, El-Zeky F
and Eltorky M: Changing trends in the distribution of the
histologic types of lung cancer: a review of 4,439 cases. Ann Diagn
Pathol. 11:89–96. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kerr KM: Pulmonary adenocarcinomas:
classification and reporting. Histopathology. 54:12–27. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Selvaggi G, Novello S, Torri V, Leonardo
E, De Giuli P, Borasio P, et al: Epidermal growth factor receptor
overexpression correlates with a poor prognosis in completely
resected non-small-cell lung cancer. Ann Oncol. 15:28–32. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fontanini G, Vignati S, Bigini D, Mussi A,
Lucchi H, Angeletti CA, et al: Epidermal growth factor receptor
(EGFr) expression in non-small cell lung carcinomas correlates with
metastatic involvement of hilar and mediastinal lymph nodes in the
squamous subtype. Eur J Cancer. 31A:178–183. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rao C, Hu Q, Ma J, Li J, Zhang C, Shen L
and Wei Q: Comparison of the epidermal growth factor receptor
protein expression between primary non-small cell lung cancer and
paired lymph node metastases: implications for targeted nuclide
radiotherapy. J Exp Clin Cancer Res. 29:72010. View Article : Google Scholar
|
|
10
|
Veale D, Kerr N, Gibson GJ, Kelly PJ and
Harris AL: The relationship of quantitative epidermal growth factor
receptor expression in non-small cell lung cancer to long term
survival. Br J Cancer. 68:162–165. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scagliotti GV, Selvaggi G, Novello S and
Hirsch FR: The biology of epidermal growth factor receptor in lung
cancer. Clin Cancer Res. 10:4227s–4232s. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jänne PA, Engelman JA and Johnson BE:
Epidermal growth factor receptor mutations in non-small-cell lung
cancer: implications for treatment and tumor biology. J Clin Oncol.
23:3227–3234. 2005.PubMed/NCBI
|
|
13
|
Eberhard DA, Giaccone G and Johnson BE;
Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to
epidermal growth factor receptor inhibitors in Non-Small-Cell Lung
Cancer Working Group: standardization for use in the clinical trial
setting. J Clin Oncol. 26:983–994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rowinsky EK: The erbB family: targets for
therapeutic development against cancer and therapeutic strategies
using monoclonal antibodies and tyrosine kinase inhibitors. Annu
Rev Med. 55:433–457. 2004. View Article : Google Scholar
|
|
16
|
Araújo A, Ribeiro R, Azevedo I, Coelho A,
Soares M, Sousa B, et al: Genetic polymorphisms of the epidermal
growth factor and related receptor in non-small cell lung cancer -
a review of the literature. Oncologist. 12:201–210. 2007.PubMed/NCBI
|
|
17
|
Choi JE, Park SH, Kim KM, Lee WK, Kam S,
Cha SI, et al: Polymorphisms in the epidermal growth factor
receptor gene and the risk of primary lung cancer: a case-control
study. BMC Cancer. 7:1992007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nomura M, Shigematsu H, Li L, Suzuki M,
Takahashi T, Estess P, et al: Polymorphisms, mutations, and
amplification of the EGFR gene in non-small cell lung cancers. PLoS
Med. 4:e1252007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
|
|
20
|
Kageyama R, Merlino GT and Pastan I: A
transcription factor active on the epidermal growth factor receptor
gene. Proc Natl Acad Sci USA. 85:5016–5020. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen LL, Clawson ML, Bilgrami S and
Carmichael G: A sequence-specific single-stranded DNA-binding
protein that is responsive to epidermal growth factor recognizes an
S1 nuclease-sensitive region in the epidermal growth factor
receptor promoter. Cell Growth Differ. 4:975–983. 1993.
|
|
22
|
Liu W, Innocenti F, Wu MH, Desai AA, Dolan
ME, Cook EH Jr and Ratain MJ: A functional common polymorphism in a
Sp1 recognition site of the epidermal growth factor receptor gene
promoter. Cancer Res. 65:46–53. 2005.PubMed/NCBI
|
|
23
|
Johnson AC, Ishii S, Jinno Y, Pastan I and
Merlino GT: Epidermal growth factor receptor gene promoter.
Deletion analysis and identification of nuclear protein binding
sites. J Biol Chem. 263:5693–5699. 1988.PubMed/NCBI
|
|
24
|
Kageyama R, Merlino GT and Pastan I:
Epidermal growth factor (EGF) receptor gene transcription.
Requirement for Sp1 and an EGF receptor-specific factor. J Biol
Chem. 263:6329–6336. 1988.PubMed/NCBI
|
|
25
|
Grinstein E, Jundt F, Weinert I, Wernet P
and Royer HD: Sp1 as G1 cell cycle phase specific transcription
factor in epithelial cells. Oncogene. 21:1485–1492. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McKibbin T, Zhao W, Tagen M, Daw NC,
Furman WL, McGregor LM, et al: Epidermal growth factor receptor
polymorphisms and risk for toxicity in paediatric patients treated
with gefitinib. Eur J Cancer. 46:2045–2051. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bandrés E, Barricarte R, Cantero C,
Honorato B, Malumbres R, Zárate R, et al: Epidermal growth factor
receptor (EGFR) polymorphisms and survival in head and neck cancer
patients. Oral Oncol. 43:713–719. 2007.
|
|
28
|
Liu G, Gurubhagavatula S, Zhou W, Wang Z,
Yeap BY, Asomaning K, et al: Epidermal growth factor receptor
polymorphisms and clinical outcomes in non-small-cell lung cancer
patients treated with gefitinib. Pharmacogenomics J. 8:129–138.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gregorc V, Hidalgo M, Spreafico A, Cusatis
G, Ludovini V, Ingersoll RG, et al: Germline polymorphisms in EGFR
and survival in patients with lung cancer receiving gefitinib. Clin
Pharmacol Ther. 83:477–484. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shepherd FA, Crowley J, Van Houtte P, et
al: The international Association For the Study of Lung Cancer
Staging Project: proposals regarding the clinical staging of small
cell lung cancer in the forthcoming (seventh) edition of the tumor
node, metastasis classification for lung cancer. J Thorac Oncol.
2:1067–1077. 2007. View Article : Google Scholar
|
|
31
|
Nagashio R, Sato Y, Matsumoto T, Kageyama
T, Satoh Y, Shinichiro R, et al: Expression of RACK1 is a novel
biomarker in pulmonary adenocarcinomas. Lung Cancer. 69:54–59.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kato T, Daigo Y, Aragaki M, Ishikawa K,
Sato M, Kondo S and Kaji M: Overexpression of MAD2 predicts
clinical outcome in primary lung cancer patients. Lung Cancer.
74:124–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu SG, Chang YL, Lin JW, et al: Including
total EGFR staining in scoring improves EGFR mutations detection by
mutation-specific antibodies and EGFR TKIs response prediction.
Plos One. 6:e233032011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH,
Hsu YC, et al: Frequent epidermal growth factor receptor gene
mutations in malignant pleural effusion of lung adenocarcinoma. Eur
Respir J. 32:924–930. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han HS, Eom DW, Kim JH, Kim KH, Shin HM,
An JY, et al: EGFR mutation status in primary lung adenocarcinomas
and corresponding metastatic lesions: discordance in pleural
metastases. Clin Lung Cancer. 12:380–386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang H, Zhou M, Shi B, Zhang Q, Jiang H,
Sun Y, et al: Identification of an exon 4-deletion variant of
epidermal growth factor receptor with increased
metastasis-promoting capacity. Neoplasia. 13:461–471.
2011.PubMed/NCBI
|
|
37
|
Sasaki H, Yukiue H, Mizuno K, Sekimura A,
Konishi A, Yano M, et al: Elevated serum epidermal growth factor
receptor level is correlated with lymph node metastasis in lung
cancer. Int J Clin Oncol. 8:79–82. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang Z, Bagheri-Yarmand R, Wang RA, Adam
L, Papadimitrakopoulou VV, Clayman GL, et al: The epidermal growth
factor receptor tyrosine kinase inhibitor ZD1839 (Iressa)
suppresses c-Src and Pak1 pathways and invasiveness of human cancer
cells. Clin Cancer Res. 10:658–667. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang D, LaFortune TA, Krishnamurthy S,
Esteva FJ, Cristofanilli M, Liu P, et al: Epidermal growth factor
receptor tyrosine kinase inhibitor reverses mesenchymal to
epithelial phenotype and inhibits metastasis in inflammatory breast
cancer. Clin Cancer Res. 15:6639–6648. 2009. View Article : Google Scholar
|
|
40
|
Moutinho C, Mateus AR, Milanezi F,
Carneiro F, Seruca R and Suriano G: Epidermal growth factor
receptor structural alterations in gastric cancer. BMC Cancer.
8:102008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ueno S, Mojic M, Ohashi Y, Higashi N,
Hayakawa Y and Irimura T: Asialoglycoprotein receptor promotes
cancer metastasis by activating the EGFR-ERK pathway. Cancer Res.
71:6419–6427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xue C, Wyckoff J, Liang F, Sidani M,
Violini S, Tsai KL, et al: Epidermal growth factor receptor
overexpression results in increased tumor cell motility in vivo
coordinately with enhanced intravasation and metastasis. Cancer
Res. 66:192–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Price JT, Wilson HM and Haites NE:
Epidermal growth factor (EGF) increases the in vitro invasion,
motility and adhesion interactions of the primary renal carcinoma
cell line, A704. Eur J Cancer. 32A:1977–1982. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Turner T, Chen P, Goodly LJ and Wells A:
EGF receptor signaling enhances in vivo invasiveness of DU-145
human prostate carcinoma cells. Clin Exp Metastasis. 14:409–418.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, et al: Clinical and biological features
associated with epidermal growth factor receptor gene mutations in
lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, et al: EGFR mutation and resistance of
non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Amador ML, Oppenheimer D, Perea S, Maitra
A, Cusatis G, Iacobuzio-Donahue C, et al: An epidermal growth
factor receptor intron 1 polymorphism mediates response to
epidermal growth factor receptor inhibitors. Cancer Res.
64:9139–9143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dubey S, Stephenson P, Levy DE, Miller JA,
Keller SM, Schiller JH, et al: EGFR dinucleotide repeat
polymorphism as a prognostic indicator in non-small cell lung
cancer. J Thorac Oncol. 1:406–412. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dong J, Dai J, Shu Y, Pan S, Xu L, Chen W,
et al: Polymorphisms in EGFR and VEGF contribute to non-small-cell
lung cancer survival in a Chinese population. Carcinogenesis.
31:1080–1086. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, et al: EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science.
304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, et al: Activating
mutations in the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to gefitinib. N Engl J
Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, et al: EGF receptor gene mutations are common
in lung cancers from ‘never smokers’ and are associated with
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad
Sci USA. 101:13306–13311. 2004.
|
